BIO Protocol Launches OpenLabs Platform at DeSci Berlin, Merging AI with Decentralized Biotech Funding
核心洞察
BIO Protocol (搜索) unveiled OpenLabs at DeSci.Berlin 2026, a platform integrating AI collaboration and community voting to streamline scientific research funding from idea to funded project.
The platform features two flagship AI-driven projects: RheumaAI (搜索) for rheumatology research and PeptAI (搜索) for peptide discovery, pairing human researchers with AI workflows.
BIO Protocol (搜索) has raised over $33 million through its BIO Genesis initiative, positioning itself as financial infrastructure for tokenized intellectual property and decentralized biotech governance.
At DeSci.Berlin 2026 on June 19, BIO Protocol (搜索) launched OpenLabs, a platform designed to let researchers turn raw scientific ideas into funded projects using a combination of AI collaboration and community voting. The announcement, made at KÖNIG GALERIE as part of Berlin Blockchain Week, marks a significant step in the convergence of artificial intelligence and decentralized science (DeSci).
OpenLabs integrates funding mechanisms directly into its collaborative environment. Researchers can develop projects, coordinate with community members, and secure funding all within a single interface — eliminating the need to navigate between grant portals, DAO voting dashboards, and separate collaboration tools.
"Scientific research funding has a well-known bottleneck problem. Getting a grant through traditional channels can take months, sometimes years, of paperwork, peer review, and institutional gatekeeping. Bio Protocol (搜索) thinks it has a faster lane," the project stated.
AI-Driven Research Pipelines
The OpenLabs platform pairs human researchers with AI-driven workflows for project development. Two flagship projects were highlighted at launch: RheumaAI (搜索), an AI agent focused on rheumatology research, and PeptAI (搜索), which targets peptide discovery. These projects exemplify the platform's approach to accelerating scientific inquiry through artificial intelligence.
Community members vote on which projects deserve funding, creating a decentralized alternative to the traditional grant committee model. The BIO token serves as the governance and utility token powering these decisions within Bio Protocol (搜索)'s broader ecosystem.
Financial Infrastructure for Biotech Innovation
BIO Protocol (搜索) has positioned itself as financial infrastructure for biotech innovation, using tokenized intellectual property and governance mechanisms called BioDAOs to channel capital toward scientific research. The project has raised over $33 million through its BIO Genesis initiative, providing runway to iterate on OpenLabs without immediately needing to demonstrate revenue.
The DeSci movement applies blockchain principles to scientific research, including transparent funding trails, community governance over research priorities, and tokenized ownership of intellectual property. Central to this model is the IP-NFT, a tokenized representation of rights to specific scientific research, owned collectively by DAO participants.
Market Context and Token Utility
The BIO token has served as a liquidity anchor for BioDAOs focused on various health conditions. For BIO token holders, the governance utility becomes more meaningful as OpenLabs scales, with voting on which scientific projects receive funding representing a more concrete use case than many governance tokens can claim.
The DeSci sector has seen growing momentum, with BIO Protocol (搜索) previously demonstrating the potential of AI-driven drug discovery through the identification of a peptide targeting ADHD (搜索) symptoms — an achievement that significantly shortened discovery timelines compared to traditional methods.
Regulatory Considerations
The risk that rarely gets discussed in DeSci circles is regulatory. Tokenized intellectual property in biotech sits at an uncomfortable intersection of securities law, patent law, and pharmaceutical regulation. As these projects mature from concept to actual drug discovery pipelines, the legal complexity will only increase. Establishing infrastructure for safety reviews will be essential to building institutional trust in AI-driven discovery, a crucial step as BIO Protocol (搜索)'s DAO progresses toward clinical validation.
Attracting co-investment from traditional biotech or academic institutions remains critical for distinguishing this DeSci cycle from previous hype phases. The future success of BIO Protocol (搜索)'s funded science will ultimately determine its ceiling.